Complete remission was seen in 32% at a mean time of 6.4 months, partial remission in 23% at a mean time of 5.7 months and 45% had no remission. Relapse rate was 14% at a mean time of 2.8 years during follow up. FSGS- NOS was the commonest subtype of FSGS (present in 56%), followed by tip variant in 24%, perihilar type in 10%, cellular in 9% and collapsing in 1%. IWR-1 clinical trial Persistent nephrotic proteinuria at 3rd and 6th month and presence of interstitial fibrosis and tubular atrophy >30% in renal biopsy were independent predictors of poor response

to treatment. Male gender, nephrotic proteinuria at onset, persistent nephrotic proteinuria at 3 and 6 months, renal failure at onset, persistent renal failure at 3 and 6 months, presence of hypertension, anemia, interstitial fibrosis

and tubular atrophy of >30% in renal biopsy and no remission after treatment predict the progression to CKD. Renal survival at 5 years for complete remission was 69%, partial remission was selleckchem 49% and no remission was 42%. Conclusion: FSGS-NOS was the commonest subtype(56%) in our study. Persistent nephrotic proteinuria at 6 months, interstitial fibrosis and tubular atrophy >30% and no remission after treatment were found to be independent risk factors and presence of interstitial fibrosis and tubular atrophy >30% in renal biopsy was the strong predictor for development of ESRD in our study. Renal survival at 5 years for complete remission was 69%, partial remission was 49% and no remission was 42%. ZHANG CHANGMING1, ZHANG WANFEN1, CHEN HUIMEI1, LIU CHUNBEI1, WU JUNNAN1, LI LIMIN2, SHI SHAOLIN1, ZEN KE1,2, LIU ZHIHONG1 1Research institute of nephrology, Jinling hospital, Nanjing University

School of Medicine, Nanjing, China; 2JERC-MBB, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Montelukast Sodium China Introduction: MicroRNAs (miRNAs) are stable in circulation, and their unique expression profiles can serve as fingerprints for various diseases. In this study, we determined whether human plasma miRNAs could be used as biomarkers to diagnose active focal segmental glomerulosclerosis (FSGS). Methods: Pooled plasma samples from 9 FSGS patients with nephrotic range proteinuria (active FSGS, FSGS-A) and 9 normal controls (NC), respectively, were analyzed by miRNA TaqMan Low Density Array (TLDA), and the two miRNA profiles were compared. The differentially expressed miRNAs were confirmed by real-time reverse transcription-PCR (qRT-PCR) using 32 patients of FSGS-A versus 30 NCs and 37 patients of FSGS-A versus 35 FSGS in remission (FSGS-CR), respectively. Receiver operation characteristics (ROC) curves were utilized to evaluate the specificity and sensitivity of the miRNAs in predicting FSGS. Results: TaqMan Low Density Array analysis of plasma samples identified 45 miRNAs that were elevated or detectable only in FSGS-A group.